Xeris Q1 net product revenue $21.9M (+33% pro forma); net loss $33.7M; reaffirms FY22 guidance

Xeris Biopharma Holdings, Inc.

2022-Q1 EPS reported -$0.25 revenue$22,073,000

Q1 net product revenue $21.9M, up 33% pro forma vs prior year; net loss $33.7M ($0.25/share).
Cash and investments $132.1M at quarter end; completed $100M draw on new $150M Hayfin term loan.
Affirms 2022 guidance: revenue $105M-$120M, year-end cash $90M-$110M, cash flow breakeven by end-2023.
Gvoke prescriptions topped 30,000 in Q1, retail TRx market share ~22%; launched Recorlev and Gvoke Kit.
Entered $30M securities purchase agreement with Armistice Capital; issued ~10.2M shares and warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.